Search Page

1

Cite

Share

Immunogenicity of biopharmaceuticals in laboratory animals.

Wierda D, Smith HW, Zwickl CM. Wierda D, et al. Toxicology. 2001 Feb 2;158(1-2):71-4. doi: 10.1016/s0300-483x(00)00410-8. Toxicology. 2001. PMID: 11164995 Review.

Cite

Share

2

Cite

Share

Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations.

Collinge M, Burns-Naas LA, Chellman GJ, Kawabata TT, Komocsar WJ, Piccotti JR, Shenton J, Wierda D. Collinge M, et al. Among authors: wierda d. J Immunotoxicol. 2012 Apr-Jun;9(2):210-30. doi: 10.3109/1547691X.2012.661486. Epub 2012 Mar 19. J Immunotoxicol. 2012. PMID: 22428536 Review.

Cite

Share

3

Cite

Share

Environmentally related disorders of the hematologic and immune systems.

Luster MI, Wierda D, Rosenthal GJ. Luster MI, et al. Among authors: wierda d. Med Clin North Am. 1990 Mar;74(2):425-40. doi: 10.1016/s0025-7125(16)30571-5. Med Clin North Am. 1990. PMID: 2181213 Review.

Cite

Share

4

Cite

Share

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. Ponce R, et al. Among authors: wierda d. Regul Toxicol Pharmacol. 2009 Jul;54(2):164-82. doi: 10.1016/j.yrtph.2009.03.012. Epub 2009 Apr 2. Regul Toxicol Pharmacol. 2009. PMID: 19345250

Cite

Share

5

Cite

Share

Toxicity of platinum complexes on hemopoietic precursor cells.

Wierda D, Pazdernik TL. Wierda D, et al. J Pharmacol Exp Ther. 1979 Dec;211(3):531-8. J Pharmacol Exp Ther. 1979. PMID: 512918

Cite

Share

6

Cite

Share

Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.

Piccotti JR, Lebrec HN, Evans E, Herzyk DJ, Hastings KL, Burns-Naas LA, Gourley IS, Wierda D, Kawabata TT. Piccotti JR, et al. Among authors: wierda d. J Immunotoxicol. 2009 Mar;6(1):1-10. doi: 10.1080/15476910802656440. J Immunotoxicol. 2009. PMID: 19519157

Cite

Share

7

Cite

Share

Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.

Komocsar WJ, Blackbourne JL, Halstead CA, Winstead CJ, Wierda D. Komocsar WJ, et al. Among authors: wierda d. J Immunotoxicol. 2016;13(1):7-19. doi: 10.3109/1547691X.2014.994793. Epub 2015 Sep 4. J Immunotoxicol. 2016. PMID: 25585959

Cite

Share

8

Cite

Share

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA. Mire-Sluis AR, et al. Among authors: wierda d. J Immunol Methods. 2004 Jun;289(1-2):1-16. doi: 10.1016/j.jim.2004.06.002. J Immunol Methods. 2004. PMID: 15251407

Cite

Share

9

Cite

Share

Age-related changes in production of interleukin-7 (IL-7) by murine long-term bone marrow cultures (LTBMC).

Updyke LW, Cocke KS, Wierda D. Updyke LW, et al. Among authors: wierda d. Mech Ageing Dev. 1993 Jun;69(1-2):109-17. doi: 10.1016/0047-6374(93)90075-3. Mech Ageing Dev. 1993. PMID: 8377525

Cite

Share

10

Cite

Share

Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?

Black LE, Green JD, Rener J, Dayan A, Cavagnaro JA, Spindler P, Bussiere JL, Bouchard P, Inoue T, Thomas PT, Essayan DM, Gillett NA, Hart TK, Hastings K, House RV, Latta D, Liminga U, Treacy G, Wierda D. Black LE, et al. Among authors: wierda d. Hum Exp Toxicol. 2000 Apr;19(4):205-7. doi: 10.1191/096032700678815855. Hum Exp Toxicol. 2000. PMID: 10918508 No abstract available.

Cite

Share